Nature Reviews Rheumatology

Papers
(The TQCC of Nature Reviews Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Inflammatory arthritis affects men’s fertility525
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis401
Polygenic risk scores outperform other tests in AS342
Bimekizumab effective across the axSpA spectrum314
No benefit from adding MTX to ustekinumab275
Targeting articular Mmp13 in OA255
Low-dose rituximab can go even lower248
Genome-wide mutagenesis reported in systemic sclerosis227
Rheumatic diseases on the rise209
Osteoarthritis risk factors differ between sexes205
A role for TGFβ and EBV in MIS-C pathogenesis175
Biological and clinical roles of IL-18 in inflammatory diseases166
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations160
New drug formulation reduces bone loss159
Ageing stem cells hold the key to age-related bone degeneration156
FOXP3 splice variant is associated with autoimmune disease144
Towards better management of sterile bone inflammation141
Use of platelet-rich plasma for knee OA not supported by RCT results140
Which NSAIDs are best for OA treatment?132
Down syndrome: insights into autoimmune mechanisms125
Inflammation across tissues: can shared cell biology help design smarter trials?119
MIS-C: myths have been debunked, but mysteries remain110
Urchin-like nanoparticles for miRNA therapy of OA103
2021 ACR guideline for JIA reflects changes in practice101
The value of comparative efficacy studies in informing rheumatology guidelines100
The 2022 ACR vaccination guideline: a call-to-action100
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?95
To choose or not? The value of discrete-choice experiments in rheumatology94
Appraising the evolving landscape of protease inhibition in osteoarthritis93
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician92
Co-trimoxazole reduces mortality in anti-MDA5-DM91
Low-dose glucocorticoids benefit seniors with RA89
Rheumatology in the digital health era: status quo and quo vadis?84
Fumarate drives interferon release in systemic sclerosis monocytes82
S100A4 inhibition targets fibrosis in SSc81
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis80
Wnt-induced IGF1 drives OA76
Calprotectin tracks tocilizumab-treated RA76
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?75
Author Correction: Proposals for the rheumatological use of JAK inhibitors74
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician74
Guiding ILD management in systemic autoimmune rheumatic diseases73
Rheumatic diseases and metabolism: where centre and periphery meet73
A direct link between SARS-CoV-2 and bone loss71
Low back pain is a growing concern69
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis68
Antibiotics keep rheumatic heart disease at bay68
sCD13 role in arthritis mediated via bradykinin receptor68
Targeting the IVD clock to halt degeneration65
Insights into IVDD pathogenesis in 202464
Erosive cargo from synovial fibroblasts63
Which DMARD for ICI-associated arthritis?62
PGE2 receptor antagonist has potential to treat osteoarthritis60
Macrophage-coated nanocarriers for gouty arthritis58
ERAP1 and the return of the UPR in ankylosing spondylitis58
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus58
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases58
Chimeric receptors broaden the therapeutic landscape for autoimmune disease57
A path towards personalized medicine for autoinflammatory and related diseases57
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative55
CAR T cells induce drug-free SLE remission55
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach54
Antibodies induce fibromyalgia symptoms53
Blocking CDK7 attenuates inflammatory arthritis52
PPIs linked to increased risk of knee replacement52
RA risk from occupational inhalation51
TASL has a key role in SLE50
Mysteries of kidney-protecting parasitic infection revealed49
Two sides of management recommendations for psoriatic arthritis47
Is air pollution linked with poor response to biologics?47
Improving the design of RCTs in non-radiographic axial spondyloarthritis47
A critical view of WHO guidelines on management of low back pain47
All fibroblasts are equal, but some are more equal than others47
Repolarizing macrophages using antagomirs45
Profiling joint tissues at single-cell resolution: advances and insights44
New refinements aim to optimize articular cartilage tissue engineering43
A leading role for interferon as a treatment target in Sjögren syndrome43
New hope for B cell-targeting therapy in pSS43
New developments in electronic health record analysis42
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis42
Treg cell-inducing nanoparticles show promise for treating OA40
CXCL5 effective in mouse model of SLE40
DNA methylation inhibitor resets tolerance in autoimmune arthritis40
Piezo1 induces new bone formation in AS37
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET37
Author Correction: Glycobiology of rheumatic diseases37
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative35
AhR promotes suppressor cell function in Sjögren syndrome34
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology34
Pathogenic antibodies target stromal antigens in RA33
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism33
APOE in fat pad and synovium contributes to knee OA33
Sex- and gender-based personalized medicine in rheumatology33
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases31
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting31
Are DNA–HLA class II interactions the missing link in SLE?31
Stromal cells implicated in RA genetic risk29
Critical appraisal of serum urate targets in the management of gout29
Imaging for prediction of RA development28
B cell X-chromosome inactivation is faulty in SLE27
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade26
HLA autoimmunity risk alleles influence T cell receptor sequences26
New OA risk factors and drug targets revealed26
BiTE therapy for rheumatic diseases25
FABP4 exacerbates RA24
Shifting the SLE management paradigm: challenges and implications23
Interferon disrupts immune and tissue homeostasis in SLE via CXCL1322
Post-transcriptional checkpoints in autoimmunity21
Mechanisms and clinical implications of intervertebral disc calcification20
Guselkumab effective through 2 years in PsA trial19
COVID-19 linked to rise in anti-MDA5 autoimmunity19
Busting the myth of methotrexate chronic hepatotoxicity18
Adropin inhibits fibrosis in SSc18
Notch signalling mediates OA pain in mice18
PLG nanoparticles target inflammatory monocytes in SSc18
Detachment promotes RA synovial fibroblast survival and invasiveness18
Multi-omics reveals distinct MPA subtypes18
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis17
Complement therapeutics are coming of age in rheumatology17
State-of-the-art evidence in the treatment of systemic sclerosis17
The potential contribution of in silico studies to improved treatment of osteoarthritis16
Citrulline immunity in RA: CD8+ T cells enter the scene16
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells16
Tildrakizumab shows promise in phase IIb study16
Treatment of non-systemic juvenile idiopathic arthritis15
How the COVID-19 pandemic has affected rheumatology research15
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer15
Update on the pathophysiology and treatment of primary Sjögren syndrome14
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms14
UNC93B1 variants promote SLE via TLR activation13
The immune health metric as an indicator of health and disease13
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions13
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk13
Primary care rheumatology: towards sustainable development in health13
Shedding light onto the immunometabolic effects of glucocorticoids13
Targeting calcium-related mechanotransduction in early OA13
Undiagnosed axSpA is prevalent in IBD12
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions12
Bone-modifying drugs slow OA progression12
Genome editing to define the function of risk loci and variants in rheumatic disease12
No benefit to intensive urate lowering in gout12
Glycosylation switch in synovial fibroblasts promotes ECM degradation12
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?11
Lupus ABC spearheading a new era of collaboration to advance lupus drug development11
Combination therapy for Behçet uveitis11
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications11
The PU.1– IL-9 axis in TH9 cells promotes RA11
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy11
Reversal of inflammatory priming prevents arthritic flares10
New guide calls for interdisciplinary approach to TMJ arthritis symptoms10
Interleukin-2 and regulatory T cells in rheumatic diseases10
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies9
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy9
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?9
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition9
Rheumatology resources need reform to represent all patients9
T cell differentiation in Sjögren syndrome is regulated by TOX9
Evidence-Based Guideline for the management of osteoporosis in men9
Advances in the calculation of minimal important change estimates for patient-reported outcome measures9
Paediatric glucocorticoid toxicity index: new possibilities in assessment9
0.1084508895874